Colchicine Trials Suggest That Some Risk Groups May Be The Most Beneficial.

2021-01-28   |   by CusiGO

An international team testing colchicine as an early treatment for cowid has released the first details of their expected results. After more than 4000 volunteers were tested, their data showed that for every 64 people treated, the drug could avoid hospitalization, which would improve if patients’ choices were fine tuned. For example, a draft by researchers led by Jean Claude tardif of the Montreal Heart Institute in Canada suggests that older men with diabetes may be one of the most high-risk groups to benefit from early colchicine treatment.

Scientist Eric Topol, one of the 10 most cited researchers in the world, welcomed the discovery. “Because it’s a tablet, it’s safe, it’s cheap (3 Euro per patient), and it’s early treatment, these results are very encouraging,” said tobol, director of the Scripps Institute of translation in La Jola, USA. Colchicine is a kind of medicine extracted from wild saffron. Saffron is a kind of medicinal plant, and its anti-inflammatory properties have been known as early as ancient Egypt.

The scientific community has successfully developed a coronavirus vaccine in a record time, but it has not achieved the same success in finding a treatment. At present, in addition to monoclonal antibodies, high-risk groups have no treatment options in the early stage of the disease, and each patient may spend tens of thousands of euros.

Tardif’s team gave colchicine to about 2000 volunteers who took covid and a lie pill to another 2000 volunteers. All subjects had some risk factors, such as obesity, hypertension or heart disease. The hospitalization rate in the colchicine group was 4.5%, while that in the other group was nearly 6%, a relative decrease of 25%. “In the context of a pandemic with thousands of cases per day, one in 64 patients receiving treatment has a reduced demand for hospitalization, which may be a related result,” said Jesus Sierra, coordinator of the registry of the Spanish hospital pharmacy Association (SEFH). Drugs associated with reducing the mortality of covid. “Colchicine is not a treatment that can be promoted, but it can guide treatment very well,” added Cera, a pharmacist at Jerez della Frontera University Hospital in Cadiz.

Cardiologist Jos é Luis L ó PEZ sendon, the lead researcher at the Spanish branch of colchicine research, who studied 250 patients, said: “64 patients received preventive hospitalization, which is a very good number. The doctor put the number in context. Lopez sendon believes that some drugs used in cardiology, such as ACEI for the treatment of hypertension or heart failure, need years of treatment before they can obtain significant benefits in one of them, such as avoiding heart attack Researchers at the University Hospital of La Paz in Madrid stressed: “the price is ridiculous, it reduces the number of people in hospital.”.

Other experts are skeptical. The initial plan of the Jean Claude tardif team was to include 6000 patients in their trial, but the researchers explained that they decided to terminate the trial early because of logistical problems and their willingness to report their positive results quickly in the severe situation of the third pandemic. Martin Landray, an epidemiologist at Oxford University, said the authors had completed the study before they had a clear answer about the effectiveness of colchicine for covid. “We all want to get results as soon as possible, but a clear result tomorrow is much more useful than an uncertain result today,” Landry criticized on social media.

Researchers at Oxford University are responsible for a large-scale clinical trial recovery in more than 175 hospitals in the UK, which aims to find an effective treatment for CVID. The platform has ruled out three options that seemed promising at the start of the pandemic: hydroxychloroquine, azithromycin, and cocktail of antiviral drugs lobinavir and ritonavir. Recovery studies also confirmed in June that dexamethasone, another anti-inflammatory drug, such as colchicine, reduced mortality in hospitalized patients with severe complications of covid by a third.

Over the past two months, the UK team has recruited more than 7500 volunteers to assess whether colchicine can reduce the number of deaths, the need for mechanical ventilation and the length of hospital stay. Their results will be released in the next few weeks. Tardif and l ó PEZ sendon’s study only achieved statistically significant benefits in reducing the number of inpatients. Pharmacist Jesus Sierra further stressed that the proportion of women in the colchicine treatment group was higher: 55.4%, while the proportion of women taking fake tablets was 52.5%. Because men are at higher risk for severe cowid, different sex ratios may artificially increase the benefits of the colchicine group. According to Sierra, this difference is not enough to explain the decrease in the number of hospitalized drug users.

“The ultimate answer will be rehabilitation,” said Domingo Pasqual figal, director of Cardiology at Notre Dame Murcia. His team has just completed a small trial of 100 hospitalized patients, nearly 6% of whom had clinical deterioration in colchicine, compared with nearly 14% of those who did not take colchicine. “My impression is that colchicine won’t make you faster and better, but it won’t make you worse,” Pascal figal said. The scientists hypothesized that the anti-inflammatory drug may help control the excessive inflammatory response in some coronavirus infected people. However, cardiologists believe that great caution is needed at the moment: “we need more consistent data.”

The 4000 patients led by Jean Claude tardif came from Canada, the United States, Spain, South Africa, Brazil and Greece. On Sunday, Greek authorities included colchicine in their treatment of covid patients, who have some risk factors and are always under medical supervision. Details of the international study show that about 14% of patients treated with colchicine have diarrhea, compared with only 7% of patients taking fake tablets. In the colchicine group, 11 cases of pulmonary embolism were also detected, i.e. thrombus blocking the pulmonary artery, compared with two cases recorded in other subjects. “The overdose of PE is definitely random,” said Jos é Luis L ó PEZ sendon, a Spanish co-author of the study.

Alberto cecconi, an Italian cardiologist, made a rough statistic at the hospital madrileno de la princessa: if Spain registered 37000 new cases of covid in one day and 20000 of them had any risk factors, then if the same percentage is reached, 1180 people will be hospitalized in the next few days. It was observed in international trials. “The colchicine program will save 280 hospital costs for today’s new cases. “Let’s imagine if we double that benefit every day in the third wave,” cecconi explained. “Colchicine is not a panacea, but it can alleviate the situation in hospitals,” he said.

You can write to us Manuel Or follow topics on Facebook, twitter, instagram, or subscribe to our newsletters here.